Literature DB >> 8998404

Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice.

P Simon1, C Hémet, C Ramassamy, J Costentin.   

Abstract

Previously established dose-response curves indicated that modafinil 20-40 mg/kg i.p. elicited in mice an obvious stimulation of locomotor activity roughly similar to that induced by (+)amphetamine 2-4 mg/kg. The effects of various agents modifying dopamine transmission were compared on the locomotor response to both drugs. The preferential D2 dopamine receptor antagonist haloperidol 37.5-150 micrograms/kg i.p. suppressed the stimulant effect of (+)amphetamine in a dose dependent manner, but not that of modafinil. The D1 dopamine receptor antagonist SCH 23390 (7.5-30 micrograms/kg s.c.) reversed the (+)amphetamine but not the modafinil induced hyperactivity. The tyrosine hydroxylase inhibitor alpha-methyl-para-tyrosine (200 mg/kg) suppressed the hyperactivity induced by 4 mg/kg dexamphetamine but not that induced by 20 mg/kg modafinil. Associating L-DOPA 150 mg/kg and benserazide 37.5 mg/kg with (+)amphetamine 2 mg/kg resulted in stereotyped climbing behavior, that was not observed with modafinil 10-80 mg/kg. The profound akinesia induced by reserpine (4 mg/kg s.c.; 5 h before testing) was reversed by (+)amphetamine 2 mg/kg but not by modafinil 40 mg/kg. Finally, on synaptosomes prepared from mouse striata preloaded with [3H]dopamine, modafinil 10(-5) M did not increase the spontaneous [3H]dopamine release whereas (+)amphetamine, at the same concentration, doubled it. From all these differences between the two drugs, it is concluded that the mechanism underlying the modafinil induced stimulant locomotor effect differs completely from that of (+)amphetamine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8998404     DOI: 10.1016/0924-977x(95)00041-m

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  29 in total

Review 1.  Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up.

Authors:  C Guilleminault; R Pelayo
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil.

Authors:  Jared W Young; Klaas Kooistra; Mark A Geyer
Journal:  Neuropsychopharmacology       Date:  2011-03-16       Impact factor: 7.853

Review 4.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  A retrospective review of supratherapeutic modafinil exposures.

Authors:  Shaun D Carstairs; Andrew Urquhart; Justin Hoffman; Richard F Clark; F Lee Cantrell
Journal:  J Med Toxicol       Date:  2010-09

6.  Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.

Authors:  Steven B Harrod; M Lee Van Horn
Journal:  Pharmacol Biochem Behav       Date:  2009-09-17       Impact factor: 3.533

7.  The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.

Authors:  John A Gruner; Val R Marcy; Yin-Guo Lin; Donna Bozyczko-Coyne; Michael J Marino; Maciej Gasior
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

8.  Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.

Authors:  Heather A Mitchell; James W Bogenpohl; L Cameron Liles; Michael P Epstein; Donna Bozyczko-Coyne; Michael Williams; David Weinshenker
Journal:  Pharmacol Biochem Behav       Date:  2008-07-25       Impact factor: 3.533

9.  A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Thomas Rugino
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

10.  Modafinil in the treatment of excessive sleepiness.

Authors:  Jonathan R L Schwartz
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.